OncoTherapy Science Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Junichi Shimada

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.8yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO

Junichi Shimada (62 yo)

1.8yrs

Tenure

Mr. Junichi Shimada is President, Chief Executive Officer of OncoTherapy Science, Inc. since July 2022 and serves as its Director from June 2022.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hatsuo Kato	Executive Chairman	47yrs	no data	no data
Junichi Shimada	President	1.8yrs	no data	no data
Jae-Hyun Park	Chief Scientific Officer & Director	5.8yrs	no data	no data
Yuichi Komine	Independent External Director	9.6yrs	no data	no data
Miyako Takagi	External Auditor	19.8yrs	no data	0.014% ¥ 3.1k
Teruhisa Tajima	External Auditor	9.6yrs	no data	no data
Yuka Yamane	Auditor	2.8yrs	no data	0.023% ¥ 5.0k
Yoshio Miki	Independent External Director	1.8yrs	no data	no data

7.7yrs

Average Tenure

57yo

Average Age

Experienced Board: 30O's board of directors are considered experienced (7.7 years average tenure).

OncoTherapy Science Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022

Recent updates

OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor

Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)

OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)

OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)

OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New minor risk - Shareholder dilution

New major risk - Share price stability

Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)

OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023

Less than half of directors are independent

Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)

OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)

OncoTherapy Science, Inc. to Report Q2, 2023 Results on Nov 04, 2022

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)

OncoTherapy Science, Inc. to Report Q1, 2023 Results on Aug 05, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022

Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)

OncoTherapy Science, Inc. to Report Fiscal Year 2022 Results on May 06, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

OncoTherapy Science, Inc. to Report Q3, 2022 Results on Feb 04, 2022

Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)

OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm

OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding

Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)

OncoTherapy Science, Inc. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: €0.83

New 90-day low: €0.96

Second quarter 2021 earnings released: JP¥2.48 loss per share

New 90-day high: €1.47

OncoTherapy Science, Inc. to Report Q1, 2021 Results on Aug 07, 2020

First quarter earnings released

First quarter earnings released

CEO

Tenure

Board Members

Average Tenure

Average Age